• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[High-performance liquid chromatographic method for the determination of fenofibric acid and reduced fenofibric acid in human blood, plasma and urine].

作者信息

Abe S, Ono K, Mogi M, Hayashi T

机构信息

Grelan Pharmaceutical Co., Ltd., Tokyo, Japan.

出版信息

Yakugaku Zasshi. 1998 Oct;118(10):447-55. doi: 10.1248/yakushi1947.118.10_447.

DOI:10.1248/yakushi1947.118.10_447
PMID:9800517
Abstract

In this study, a very reliable HPLC method was developed for the determination of fenofibric acid and reduced fenofibric acid in the biological samples described as follows. After addition of the internal standard solution and 0.5 M HCl to the biological sample, fenofibric acid, reduced fenofibric acid and the internal standard were extracted with a mixed solvent of n-hexane and ethyl acetate (90:10) from the mixture. The acids were back-extracted from the organic phase with 0.1 M Na2HPO4 and then re-extracted from the aqueous phase with a mixed solution of n-hexane and ethyl acetate (95:5) after addition of 0.5 M HCl. The organic phase was evaporated to dryness under the vacuum. The residue was dissolved in MeOH and diluted with distilled water. An aliquot of the resulting solution was injected on the HPLC. High reproducibility was observed in this HPLC method (C.V.% less than 4%). Moreover it was confirmed that the conjugates in the urine could be hydrolyzed by incubation at 37 degrees C for 18 h after addition of 400 IU of beta-glucuronidase.

摘要

相似文献

1
[High-performance liquid chromatographic method for the determination of fenofibric acid and reduced fenofibric acid in human blood, plasma and urine].
Yakugaku Zasshi. 1998 Oct;118(10):447-55. doi: 10.1248/yakushi1947.118.10_447.
2
Determination of Fenofibric Acid in Rat Plasma and its Application to a Comparative Pharmacokinetic Study of JW322 and Fenofibrate.大鼠血浆中非诺贝特酸的测定及其在JW322与非诺贝特比较药代动力学研究中的应用。
Drug Res (Stuttg). 2017 Sep;67(9):534-538. doi: 10.1055/s-0043-109243. Epub 2017 May 30.
3
Determination of bezafibrate, ciprofibrate and fenofibric acid in human plasma by high-performance liquid chromatography.高效液相色谱法测定人血浆中的苯扎贝特、环丙贝特和非诺贝特酸
J Chromatogr B Biomed Appl. 1996 Dec 13;687(2):437-42. doi: 10.1016/s0378-4347(96)00254-x.
4
Development of a sensitive liquid chromatography/tandem mass spectrometry method for the determination of fenofibric acid in rat plasma.一种用于测定大鼠血浆中非诺贝特酸的灵敏液相色谱/串联质谱法的开发。
Biomed Chromatogr. 2012 Apr;26(4):497-501. doi: 10.1002/bmc.1693. Epub 2011 Sep 1.
5
Determination of fenofibric acid in human plasma using automated solid-phase extraction coupled to liquid chromatography.采用自动固相萃取结合液相色谱法测定人血浆中的非诺贝特酸。
J Chromatogr B Biomed Sci Appl. 2000 Jun 9;742(2):391-400. doi: 10.1016/s0378-4347(00)00195-x.
6
Distribution of fenofibric acid in lipoprotein fractions of patients.非诺贝特酸在患者脂蛋白组分中的分布。
Eur J Drug Metab Pharmacokinet. 1998 Apr-Jun;23(2):287-94. doi: 10.1007/BF03189353.
7
Effect of magnesium carbonate on the solubility, dissolution and oral bioavailability of fenofibric acid powder as an alkalising solubilizer.碳酸镁对作为碱化增溶剂的非诺贝特酸粉末的溶解度、溶解和口服生物利用度的影响。
Arch Pharm Res. 2016 Apr;39(4):531-538. doi: 10.1007/s12272-015-0701-9. Epub 2016 Mar 18.
8
Absolute oral bioavailability of fenofibric acid and choline fenofibrate in rats determined by ultra-performance liquid chromatography tandem mass spectrometry.采用超高效液相色谱串联质谱法测定大鼠体内非诺贝特酸和非诺贝特胆碱的绝对口服生物利用度。
Biomed Chromatogr. 2017 Apr;31(4). doi: 10.1002/bmc.3832. Epub 2016 Oct 10.
9
Urinary glucuronide excretion of fenofibric and clofibric acid glucuronides in man. Is it polymorphic?
Eur J Clin Pharmacol. 1991;41(2):153-9. doi: 10.1007/BF00265909.
10
Single-dose bioequivalence of 105-mg fenofibric acid tablets versus 145-mg fenofibrate tablets under fasting and fed conditions: a report of two phase I, open-label, single-dose, randomized, crossover clinical trials.空腹和进食条件下 105 毫克非诺贝特酸片与 145 毫克非诺贝特片的单次给药生物等效性:两项 I 期、开放标签、单次给药、随机、交叉临床试验报告。
Clin Ther. 2011 Jun;33(6):766-75. doi: 10.1016/j.clinthera.2011.05.047.

引用本文的文献

1
Development and validation of bioanalytical UHPLC-UV method for simultaneous analysis of unchanged fenofibrate and its metabolite fenofibric acid in rat plasma: Application to pharmacokinetics.用于同时分析大鼠血浆中未变化的非诺贝特及其代谢产物非诺贝特酸的生物分析超高效液相色谱-紫外法的开发与验证:在药代动力学中的应用
Saudi Pharm J. 2017 Jan;25(1):128-135. doi: 10.1016/j.jsps.2016.05.008. Epub 2016 May 26.
2
Development of self-nanoemulsifying drug delivery systems for the enhancement of solubility and oral bioavailability of fenofibrate, a poorly water-soluble drug.开发自纳米乳化药物递送系统以提高非诺贝特(一种难溶性药物)的溶解度和口服生物利用度。
Int J Nanomedicine. 2016 Jun 14;11:2829-38. doi: 10.2147/IJN.S104187. eCollection 2016.
3
Development and Validation of RP-HPLC Method for Simultaneous Estimation of Atorvastatin Calcium and Fenofibrate in Tablet Dosage Forms.用于同时测定片剂剂型中阿托伐他汀钙和非诺贝特的反相高效液相色谱法的开发与验证
Indian J Pharm Sci. 2008 Mar-Apr;70(2):263-5. doi: 10.4103/0250-474X.41473.